Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Indivior LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Shares Traded Last Trade
  -1.40p -1.16% 119.35p 642,364 14:26:17
Bid Price Offer Price High Price Low Price Open Price
119.30p 119.50p 120.95p 115.75p 118.30p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 809.24 101.43 5.92 19.2 869.2

Indivior (INDV) Latest News

More Indivior News
Indivior Takeover Rumours

Indivior (INDV) Share Charts

1 Year Indivior Chart

1 Year Indivior Chart

1 Month Indivior Chart

1 Month Indivior Chart

Intraday Indivior Chart

Intraday Indivior Chart

Indivior (INDV) Discussions and Chat

Indivior Forums and Chat

Date Time Title Posts
21/1/201916:39RB. de-merger 507
30/12/201821:04INDIVIOR THE PILL WITH NO CHEERS OR BEERS246
31/7/201812:45Indivior (INDV) IP Battle Status -
28/7/201813:16Indivior (INDV) One to Watch on Monday 2
14/5/201812:52Indivior (INDV) Settles Legal Patent Battle -

Add a New Thread

Indivior (INDV) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
14:26:17119.55785938.47O
14:26:17119.35346412.95AT
14:26:17119.551,7412,081.37AT
14:26:17119.551,8292,186.57AT
14:25:02119.60416497.54AT
View all Indivior trades in real-time

Indivior (INDV) Top Chat Posts

DateSubject
23/1/2019
08:20
Indivior Daily Update: Indivior is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker INDV. The last closing price for Indivior was 120.75p.
Indivior has a 4 week average price of 102.40p and a 12 week average price of 75.48p.
The 1 year high share price is 504.60p while the 1 year low share price is currently 75.48p.
There are currently 728,306,837 shares in issue and the average daily traded volume is 2,068,719 shares. The market capitalisation of Indivior is £875,060,664.66.
23/11/2018
08:00
pwhite73: RNS out but it is worthless. Investors should expect a string of vacuous RNS announcements over the next few months to try and mitigate against the US court decision and boost a flagging share price.
21/11/2018
08:05
pwhite73: PWhite731 Oct '18 - 22:32 - 452 of 491 Edit 0 0 0 The writing is on the wall for this company. The share price was trading at 490p in June 2018. There are a number of problems here. 1. The opioid addiction market is too competitive and relatively easy to enter. 2. The injunction against Dr Reddy is only temporary. 3. Donald Trump and the State Department are soon to announce their own nationwide programme to combat opioid addiction in the US. The shares can be traded as it bounces off the bottom but because of the share price you need lots of upfront capital to make any decent money. Those who think the share price is about to mount a recovery are mistaken. When the next set of adverse news is released it will plunge again
01/10/2018
22:32
pwhite73: The writing is on the wall for this company. The share price was trading at 490p in June 2018. There are a number of problems here. 1. The opioid addiction market is too competitive and relatively easy to enter. 2. The injunction against Dr Reddy is only temporary. 3. Donald Trump and the State Department are soon to announce their own nationwide programme to combat opioid addiction in the US. The shares can be traded as it bounces off the bottom but because of the share price you need lots of upfront capital to make any decent money. Those who think the share price is about to mount a recovery are mistaken. When the next set of adverse news is released it will plunge again.
21/8/2018
08:44
naed: Very quite here......share price constantly loosing value?
12/7/2018
15:03
steeplejack: Good recovery today,hope this presages a favourable court review. Plus... Indivior got a boost as Bank of America Merrill Lynch upgraded the stock to 'buy' following recent share price weakness.
11/7/2018
09:15
mj19: http://www.cityam.com/289071/indivior-share-price-dives-wake-us-market-competition
16/6/2018
11:58
kazoom: I am new to Indivior so apologies if this doesn't make sense - please feel free to correct me ;-) When I read "So Dr Reddy is really interested in testing punitive damages! I do wonder." I wonder if Dr Reddy are actually engaged in some Trump style bargaining. I note here Https://www.investegate.co.uk/indivior-plc--indv-/rns/indivior-settlement-with-par-pharmaceutical/201805140700088858N/ (14-may) that INDV settled with PAR phara and that Par get the ability to sell the generic from Jan 2023 Maybe Reddy are angling for a similar settlement? Also if Par don't have the rights until 2023 - why would we expect the courts to grant a later comer like Reddy earlier access to the market? On that basis (and of course it could be nonsense) it seems to be that the outcome is likely to be much better than Friday's share price movement would suggest. Any thoughts?
02/5/2018
13:40
sarkasm: http://uk.advfn.com/stock-market/london/indivior-INDV/share-news/Indivior-PLC-1st-Quarter-Results/77315882
01/11/2017
11:47
gregmorg: Yup, as you say, who knows with this one! Good thing is it is increasingly looking a less dangerous/more secure company. So after the 2nd November we then roll on to that other tester of our investors steel --on the 14th. Will see how that coding scenario has developed . It could be the stock starts to put the days of serious uncertainty behind it. Revenues are looking good and growing very respectably. But what about the veins!~! Thinking of patience(or apathy!) I have been a little puzzled by GSK's share price performance in recent time but am hoping this baptism of fire gears up/fires up the new CEO. OR what! As for my other pharma, IMB, I do wish, Steeplejack, I had more noted your disposal some months back and so questioned my own rationale. Good call. Now I am left waiting for Vaping to kick in! Hopefully this is made less painless by a continued good stream of dividends. Let's see what tomorrow brings on IND . Unfortunately I cannot listen in to the live investors meeting as I have some silly cross country trail commitment. Hopefully I can listen in later in the day.
31/10/2017
21:06
gregmorg: Steeplejack. I understand the Committee vote at the end was 18 for and one against.The latter was on the basis of this was nothing new! This, I hasten to add, is purely my understanding. I did say this Committee is advisory but it does look as if the recommendation to the FDA is going our way. A few concerns were raised re the results of the 300mg doses( as opposed to the 100mg) and a few small issues that resulted, but this does not appear to have affected the outcome. So possibly it is looking OK!. We both have experiences of erratic share price performance across the financial reporting period so its important to maintain the longer view.
Indivior share price data is direct from the London Stock Exchange
Your Recent History
LSE
INDV
Indivior
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190123 14:43:21